EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

On the street, Lululemon founder Chip Wilson is launching a proxy fight at the athleisure company in an effort to shake up the board, nominating three director candidates, including the former co-ceeo of On Running, a former ESPN chief marketing officer, and former Activision CEO Eric Hersburg. Wilson is not trying to put himself back on the board, although he does remain Lulu's second biggest shareholder, nearly 9% stake, 10 million shares, and has long complained about the performance of Lululemon. This y ...

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's pipeline amid significant vaccine policy changes in the US. The transaction, for a price of $15.50 per share in cash, is expected to close in the first quarter of 2026. Through the deal, Sanofi will acquire Dynavax's hepatitis B vaccine HEPLISAV-B. The product won approval in the US and Europe in 2017 and 2021, respectively. Sanofi does not currently have a hepatitis B vacc ...

What AI bubble? New research from Bank of America has thrown cold water on the growing narrative, and instead focuses on the upside the firm sees in chipmakers.The firm recently laid out its forecast for the coming year in a note to clients, predicting that the AI market will experience some volatility but ultimately finish the year strong as data center buildouts continue and companies double down on manufacturing and equipment spending. The analysts view the AI market as being roughly halfway through a ...

We’re closing in on the end of 2025 at record-shattering levels for the S&P 500, and it’s not a time for complacency. In my view, now is a time for active portfolio management, and investors have to take tremendous care to ensure that ourWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular cont ...

Key Takeaways Ocugen's phase III liMeliGhT study of OCU400 in RP nears enrollment, with top-line data expected in Q4 2026.OCGN's OCU410ST for Stargardt disease is in phase II/III, with interim data expected in mid-2026.Ocugen expects phase II data for OCU410 in GA in Q1 2026, with phase III slated for mid-2026.Ocugen (OCGN) is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms of action. With all three key pipeline programs moving on schedule, Ocuge ...

nCino (NCNO) closed the last trading session at $26.29, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.73 indicates a 32.1% upside potential.The mean estimate comprises 15 short-term price targets with a standard deviation of $4.08. While the lowest estimate of $27.00 indicates a 2.7% increase from the current price level, the most optimistic analyst expects the s ...

BREAKING: Stocks Open Lower In Quiet Trade Today's Spotlight Leaderboard New Year's Sale Get a head start on your 2026 investing resolutions with 1 month of Leaderboard for only $29. Get Market Insights on IBD Live Join IBD Live to watch and discuss the market action in real time with a team of top market analysts. Is the Santa Claus Rally Real? Something big may be coming to town—check out IBD's guide to the Santa Claus Rally. (© Chris Gash) Next Data Center Roadblock For Google, Microsoft, Oracle, Meta Is ...

Key Takeaways MindMed is enrolling two phase III GAD studies with top-line data due in 2026. MNMD's phase III Emerge study in MDD enrolled faster, with top-line data now expected in mid-2026.MindMed shares rose 101.2% in six months. A $258.9M financing strengthens its balance sheet.Mind Medicine (MindMed) (MNMD) is developing its lead pipeline candidate MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate, for the treatment of generalized anxiety disorde ...

Key Points Mid-cap stocks boast a better long-term track record of performance than large caps. This hasn’t been the case of late mostly because of a once-in-a-generation tech revolution. Picking individual mid-cap tickers can be a lot of work, and so an ETF can be more sensible. 10 stocks we like better than Vanguard Index Funds - Vanguard Mid-Cap ETF › Anyone who has been in the stock market for long enough has likely heard the merits of index fund investing. They're simple to own and often pr ...